At a glance
ClinicalIndex Comparison RecordN/ACompleted· 93 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Noninterventional Study of Vimpat® (Lacosamide) as Adjunctive Antiepileptic Drug Therapy in Patients With Brain Tumor-related Epilepsy
In Brief
An observational study for Brain Tumor Related Epilepsy (BTRE). Completed, enrolled 93 participants across 24 sites in 6 countries.
Detailed Summary
This study is being conducted to find out whether lacosamide (a drug to treat epilepsy) is effective in routine clinical practice for patients with epilepsy caused by a brain tumor.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBrain Tumor Related Epilepsy (BTRE)
CountriesFrance, Germany, Italy, Netherlands, Spain, United Kingdom
CollaboratorsPRA Health Sciences
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartNov 2014
Primary CompletionDec 2017
TodayJul 2026
First PostedOct 27, 2014
Enrollment StartNov 27, 2014
Primary CompletionDec 4, 2017
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 11.7 years ago